Your browser doesn't support javascript.
loading
A Role for Oncostatin M in the Impairment of Glucose Homeostasis in Obesity.
Piquer-Garcia, Irene; Campderros, Laura; Taxerås, Siri D; Gavaldà-Navarro, Aleix; Pardo, Rosario; Vila, María; Pellitero, Silvia; Martínez, Eva; Tarascó, Jordi; Moreno, Pau; Villarroya, Joan; Cereijo, Rubén; González, Lorena; Reyes, Marjorie; Rodriguez-Fernández, Silvia; Vives-Pi, Marta; Lerin, Carles; Elks, Carrie M; Stephens, Jacqueline M; Puig-Domingo, Manel; Villarroya, Francesc; Villena, Josep A; Sánchez-Infantes, David.
Afiliação
  • Piquer-Garcia I; Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Campderros L; Department of Biochemistry and Molecular Biomedicine, and Institute of Biomedicine, University of Barcelona, Barcelona, Spain.
  • Taxerås SD; BiomedicalResearch Center (Red Fisiopatología de la Obesidad y Nutrición) (CIBEROBN), ISCIII, Madrid, Spain.
  • Gavaldà-Navarro A; Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Pardo R; Department of Biochemistry and Molecular Biomedicine, and Institute of Biomedicine, University of Barcelona, Barcelona, Spain.
  • Vila M; BiomedicalResearch Center (Red Fisiopatología de la Obesidad y Nutrición) (CIBEROBN), ISCIII, Madrid, Spain.
  • Pellitero S; Laboratory of Metabolism and Obesity, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Martínez E; Laboratory of Metabolism and Obesity, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Tarascó J; Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Moreno P; BiomedicalResearch Center (Red Fisiopatología de la Diabetes y enfermedades metabólicas) (CIBERDEM), ISCIII, Madrid, Spain.
  • Villarroya J; Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Cereijo R; Department of Surgery, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • González L; Department of Surgery, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Reyes M; Department of Biochemistry and Molecular Biomedicine, and Institute of Biomedicine, University of Barcelona, Barcelona, Spain.
  • Rodriguez-Fernández S; Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Vives-Pi M; Department of Biochemistry and Molecular Biomedicine, and Institute of Biomedicine, University of Barcelona, Barcelona, Spain.
  • Lerin C; BiomedicalResearch Center (Red Fisiopatología de la Obesidad y Nutrición) (CIBEROBN), ISCIII, Madrid, Spain.
  • Elks CM; Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Stephens JM; Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Puig-Domingo M; Immunology Section, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Villarroya F; BiomedicalResearch Center (Red Fisiopatología de la Diabetes y enfermedades metabólicas) (CIBERDEM), ISCIII, Madrid, Spain.
  • Villena JA; Immunology Section, Germans Trias i Pujol Research Institute, Barcelona, Spain.
  • Sánchez-Infantes D; Endocrinology, Sant Joan de Déu Hospital, Barcelona, Spain.
J Clin Endocrinol Metab ; 105(3)2020 Mar 01.
Article em En | MEDLINE | ID: mdl-31606738
ABSTRACT
CONTEXT Oncostatin M (OSM) plays a key role in inflammation, but its regulation and function during obesity is not fully understood.

OBJECTIVE:

The aim of this study was to evaluate the relationship of OSM with the inflammatory state that leads to impaired glucose homeostasis in obesity. We also assessed whether OSM immunoneutralization could revert metabolic disturbances caused by a high-fat diet (HFD) in mice.

DESIGN:

28 patients with severe obesity were included and stratified into two groups (1) glucose levels <100 mg/dL and (2) glucose levels >100 mg/dL. White adipose tissue was obtained to examine OSM gene expression. Human adipocytes were used to evaluate the effect of OSM in the inflammatory response, and HFD-fed C57BL/6J mice were injected with anti-OSM antibody to evaluate its effects.

RESULTS:

OSM expression was elevated in subcutaneous and visceral fat from patients with obesity and hyperglycemia, and correlated with Glut4 mRNA levels, serum insulin, homeostatic model assessment of insulin resistance, and inflammatory markers. OSM inhibited adipogenesis and induced inflammation in human adipocytes. Finally, OSM receptor knockout mice had increased Glut4 mRNA levels in adipose tissue, and OSM immunoneutralization resulted in a reduction of glucose levels and Ccl2 expression in adipose tissue from HFD-fed mice.

CONCLUSIONS:

OSM contributes to the inflammatory state during obesity and may be involved in the development of insulin resistance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncostatina M / Glucose / Homeostase / Obesidade Limite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncostatina M / Glucose / Homeostase / Obesidade Limite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2020 Tipo de documento: Article